Virtual Library
Start Your Search
P.J. Voon
Author of
-
+
P1.05 - Early Stage NSCLC (ID 691)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.05-007 - A Retrospective Study to Compare Resection Rate and Survival Rate in Operable Stage I to III NSCLC After Introduction of Lung Cancer MDT (ID 9324)
09:30 - 09:30 | Author(s): P.J. Voon
- Abstract
Background:
Multidisciplinary team (MDT) has emerged as the standard of care for lung cancer management in the past two decades.Lung cancer MDT Hospital Umum Sarawak was established in June 2013. It is a collaboration of healthcare professionals involving in lung cancer management comprising of oncologists, cardiothoracic surgeons, pulmonologists, radiologists and pathologists. Although MDT approach is widely accepted, it is poorly evaluated with limited observational data available especially in developing countries. While some studies had proven a significant benefit from MDT approach to the management of inoperable non small-cell lung carcinoma (NSCLC), comparison of resection rate in operable NSCLC is scarcely done.
Method:
Data was retrieved from Hospital Umum Sarawak lung cancer registry and individual patient’s case note. Subjects were recruited according to inclusion criteria: operable newly diagnosed histologically proven Stage I to III NSCLC, from July 2012 to June 2013 (non-MDT group), January to December 2014 and 2015 (MDT group).
Result:Table 1 illustrates the patients’ characteristics before and after introduction of MDT
Non-MDT Group MDT Group Variables July 2012 to June 2013, n (%) January to December 2014, n (%) January to December 2015, n (%) Age at Diagnosis <40 41 – 50 51 – 60 61 – 70 71 – 80 >80 0 (0.00) 4 (13.33) 6 (20.00) 10 (33.33) 6 (20.00 4 (13.33) 1 (6.67) 1 (6.67) 3 (20.00) 7 (46.67) 3 (20.0) 0 (0.00) 0 (0.00) 3 (13.00) 4 (17.40) 7 (30.40) 8 (34.80) 1 (4.40) Gender Male Female 11 (36.67) 19 (63.33) 6 (40.00) 9 (60.00) 5 (21.74) 18 (78.26) Histology Adenocarcinoma Squamous Cell Carcinoma Adeno-squamous Carcinoma Large Cell Carcinoma Others Unsure 17 (56.67) 8 (26.67) 0 (0.00) 1 (3.33) 0 (0.00) 4 (13.33) 10 (66.67) 2 (13.33) 0 (0.00) 1 (6.67) 2 (13.33) 0 (0.00) 15 (62.22) 7 (30.43) 1 (4.35) 0 (0.00) 0 (0.00) 0 (0.00) Stage I II III Unsure 2 (6.67) 3 (10.00) 21 (70.00) 4 (13.33) 2 (13.33) 3 (20.00) 7 (46.67) 3 (20.00) 3 (13.04) 2 (8.70) 14 (60.87) 4 (17.39) Table 2 illustrates the comparison of resection rates and 2-year survival rates before and after introduction of MDT
Non-MDT Group MDT Group July 2012 to June 2013 January to December 2014 January to December 2015 Number of patients with Stage I to III NSCLC (n) 30 15 23 Number of patients with resection done (n) 10 7 9 Resection rate (%) 33.3 46.7 39.1 Total number of traceable patients (n) 30 15 18 Missing data (n) 0 0 5 Number of patients survived ≥2 years (n) 10 9 12 Two-year survival rate (%) 33.3 60.0 66.7
Conclusion:
This single-centre study demonstrates a marked increase of resection rates and two-year survival rates in operable stage I to III NSCLC after introduction of lung cancer MDT. More quality evidence is yet to be explored to confirm the association between MDT approach and improvement in lung cancer outcomes.
